Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of MVA85A in Volunteers Latently Infected With TB.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria~* Healthy adults aged 18 to 50 years~* Resident in or near Oxford for the duration of the vaccination study~* Willingness to allow the investigators to discuss the volunteer's medical history with the volunteer's GP~* Screening Elispot positive (more than 50 spots/million PBMC) for at least any 1 of the 3 ESAT6 peptide pools or any one of the 3 CFP10 pools ; and screening Elispot positive for PPD.~* Heaf test grade II-IV or positive Mantoux test.~* CXR normal; or abnormal but not clinically significant CXR findings with no evidence of past/present TB infection or disease on the CXR.~* For females only, willingness to practice continuous effective contraception during the study and a negative pregnancy test on the day of vaccination~* Agreement to refrain from blood donation during the course of the study~* Written informed consent~* Willingness to undergo an HIV~Exclusion Criteria~* Any deviation from the normal range in biochemistry or haematology blood tests or in urine analysis~* Heaf grade IV~* Prior receipt of a recombinant MVA or Fowlpox vaccine~* Use of any investigational or non-registered drug, live vaccine or medical device other than the study vaccine within 30 days preceding dosing of study vaccine, or planned use during the study period~* Administration of chronic (defined as more than 14 days) immunosuppressive drugs or other immune modifying drugs within six months of vaccination. (For corticosteroids, this will mean prednisolone, or equivalent, ε 0.5 mg/kg/day. Inhaled and topical steroids are allowed.)~* Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection and asplenia~* History of allergic disease or reactions likely to be exacerbated by any component of the vaccine, e.g. egg products~* Evidence of cardiovascular disease~* History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ)~* History of insulin requiring diabetes mellitus~* Chronic or active neurological disease requiring ongoing specialist supervision

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).